Search results
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
StreetInsider· 6 days agoMikal Watts, who is representing 89-year-old Angela Valadez, said the companies knew that Zantac’s active ingredient, ranitidine, would turn into a cancer-causing substance called NDMA as it ...
Here's Why GSK (GSK) is a Strong Value Stock
Zacks via Yahoo Finance· 2 hours agoUtilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. GSK (...
GSK plc (NYSE:GSK) Given Average Rating of “Hold” by Analysts
ETF DAILY NEWS· 1 day agoShares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering ...
Pfizer Agrees to Settle More than 10,000 Zantac Cancer Lawsuits
Bloomberg Law· 2 hours agohas agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation. The ...
GSK Plc ADR (GSK) Shares Soar Above 1-Year High – News Heater
NewsHeater· 1 day agoGSK Plc ADR (NYSE: GSK)’s stock price has gone rise by 1.40 in comparison to its previous close of 43.45, however, the company has experienced a 6.32% increase ...
BioVersys and GSK expand their partnership for TB treatment alpibectir
Pharmaceutical Technology via Yahoo Finance· 7 hours agoBioVersys and GSK have announced the expansion of their strategic partnership to expedite the...
GSK expands collaboration with BioVersys on tuberculosis asset alpibectir
Seeking Alpha· 22 hours agoGSK expands collaboration with BioVersys AG and invests in their latest funding round, propelling...
Earnings call: GSK forecasts growth with strong Q1 performance By Investing.com
Investing.com· 4 days agoGSK upgraded its full-year guidance, expecting another year of substantial growth for shareholders,...
GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. via Yahoo Finance· 6 days agoGSK (LON:GSK) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q...
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C...
Benzinga· 1 day agoStrategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended
